Biota Holdings (BTA)

Shares / Stock Code

BTA

Stock Exchange / Sharemarket

Australian Securities Exchange

Biota Holdings (BTA) is a leading anti-infective drug developer. The Company receives royalties for its discovery of a pharmaceutical drug Relenza and it has key partnerships with other companies for the commercialisation and development of its products. Biota was listed on the Australian Stock Exchange (ASX) on 20th December, 1985 and its headquarter is located in Melbourne.

Zanamivir, discovered by Biota is a neuraminidase inhibitor used to cure influenza. GlaxoSmithKline (GSK) holds the license for the marketing of Zanamivir under the trade name Relenza. Relenza targets seasonal influenza. A series of candidate drugs targeting respiratory syncytial virus (RSV) disease are developed by BTA, and are licensed to AstraZeneca. Apart from respiratory diseases Biota’s research pipeline also include early stage research focusing the treatment of the hepatitis C virus (HCV). Boita’s novel nucleoside analogues, aimed at hepatitis C virus (HCV) infections are licensed to Boehringer Ingelheim. Inverness Medical is a licensed marketer of Biota’s influenza diagnostic developments under the brands BioStar OIA FLU and BioStar OIA FLU A/B. Daiichi-Sankyo has a license arrangement with BTA for the development of Biota’s second generation influenza anti-virals known as LANI or long-acting inhaled neuraminidase inhibitors.

On 31 July, 2008, BTA completed the initial Phase II clinical study of CS-8958, its second generation influenza treatment, in Japan. On 11th August, 2008, Biota’s human rhinovirus (HRV) program entered into initial dosing of its Phase IIa clinical trial. Biota Holdings is also doing SARS research for the US Army Medical Research Institute.

Biota Holdings History

Biota Holdings listed on the Australian Stock Exchange in 1985. It entered into a licensing arrangement with GlaxoSmithKline for the development and marketing of Relenza in 1990. In the mid 90s, Biota included further products into its current product pipeline in order to ensure its long-term growth. In 2003, the Company relocated its offices and research facilities to Notting Hill (Victoria).

Biota Holdings (BTA) Products and Services

  • Anti infectives with focus on antivirals, particularly respiratory infection drugs

Biota Holdings (BTA) Locations and Subsidiaries

Biota Holdings Head Office
10/585 Blackburn Road,
Notting Hill, VIC, Australia, 3168
Phone: +61 3 9915 3700
Fax: +61 3 9915 3702
Email: info@biota.com.au

Biota Holdings Subsidiaries

Biota Scientific Management Pty Ltd
Biota Investments Pty Ltd
Biota Respiratory Research

Trading Names

Biota Holdings Limited

Other Biota Holdings Details

Biota Holdings Year Established: 1985
ACN: 006 479 081
D-U-N-S: 753413921
ABN: 28006479081

Biota Holdings (BTA) Share Price

Submitted by ASX Listed Company on 14 May, 2009 - 20:06

Download our FREE App


Signup for Free
Don't miss out on your free share trading articles.


Free Risk Money Management Calculator for those who sign up!